Clinical trial support organisation Medical Research Network (MRN) has won a Queen’s Award for Enterprise for International Trade for its work in helping enhance the delivery of clinical trials through decentralisation technology.
The Queen’s Awards
Established in 1965, The Queen’s Awards for Enterprise are the most prestigious business awards in the UK. They celebrate the success of exciting and innovative businesses which are leading the way with products or services, and are delivering social mobility programmes or sustainable development practices.
MRN offers the market a range of platforms designed to facilitate decentralised clinical trials (DCT). The company’s Home Trial Support service takes clinical trial research visits to patients in their own community, wherever they live around the world. The platform has been designed to support patients, research sites, and drug developers by combining an integrated suite of clinical, personnel and digital/eClinical DCT elements, enhancing the delivery of clinical trials making them faster, more flexible, efficient and improving data quality.
Founded in 2006, MRN has since seen international growth and has over 330 employees, with offices in the UK, USA, Germany, Spain and Japan. The company delivers clinical trials in over 50 countries through the deployment of healthcare professionals and the integration of digital technology.
Graham Wylie, Founder and CEO, said: “We are honoured to receive this prestigious award as it recognises the incredible growth of our business and the dedication and persistence of our employees, global network of healthcare professionals, vendors and partners. We are a company that is dedicated to making healthcare more accessible for patients, clinical trials less burdensome for families and helping bring new medicines to people faster.”
Stuart Redding (COO), added: “We will continue to drive the decentralised clinical trial market, as we have for 16 years, by continuing to innovate, expand our geographical reach, enhance our DCT solutions with digital technology and expanding our portfolio of services organically and through acquisitions. We do this to deliver clinical trials to patients in their own communities around the globe efficiently. This award is a further validation of our position as the catalysts of DCTs, designing and scaling trials quickly and efficiently, bringing medicines to market faster.”